Discontinuation report TEVA-RISEDRONATE
| Report ID | 133905 |
| Drug Identification Number | 02413809 |
| Brand name | TEVA-RISEDRONATE |
| Common or Proper name | RISEDRONATE 150MG TABLET |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | RISEDRONATE SODIUM |
| Strength(s) | 150MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | PP 3 |
| ATC code | M05BA |
| ATC description | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2021-02-05 |
| Remaining supply date | 2021-02-05 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | Item is disc |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2021-02-12 | English | Compare |
| v2 | 2021-02-12 | French | Compare |
Showing 1 to 2 of 2